David Knopman (Mayo Clinic via YouTube)
A second adcomm member abandons his post in aftermath of controversial aducanumab decision
As the fallout from the FDA’s approval of Alzheimer’s med aducanumab grows, a second member of the adcomm overseeing that drug’s review has walked away …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
